Conference Coverage
Clinical Insights
The power and promise of social media in oncology
Dr. Alan Lyss describes a recent presentation on the role of social media in oncology.
Conference Coverage
For cervical cancer screening, any strategy is acceptable
Plus, an expert explains why increased rates of HPV vaccination may affect future screening guidelines.
Conference Coverage
Success in LGBTQ+ medicine requires awareness of risk
Cross-sex hormone therapy is a life-sustaining treatment that should be viewed analogously with any other long-term management strategy, such as...
Conference Coverage
Superior survival with sintilimab in squamous NSCLC
Sintilimab improved overall and progression-free survival, when compared with docetaxel.
Conference Coverage
Psoriasis associated with an increased risk of COVID-19 in real-world study
Those treated with TNF-alpha inhibitors, methotrexate, and apremilast had statistically lower risks of COVID-19 vs. those on topical therapy.
Conference Coverage
Is it time for universal genetic testing in colorectal cancer?
A new study supports multigene panel testing for all colorectal cancer patients.
Clinical Insights
IMvigor130: A treasure trove of data for urothelial carcinoma
Dr. Alan Lyss reviews updated results with atezolizumab in locally advanced or metastatic urothelial carcinoma.
Conference Coverage
Cushing’s death rate ‘unacceptable,’ triple that of general population
Death rates among patients with endogenous Cushing’s syndrome have dropped since 2000 but are still threefold that of the general population.
Conference Coverage
Cell-free DNA improves response prediction in breast cancer
Using cell-free DNA and MRI in combination improved prediction of pathological complete response.
Conference Coverage
Tislelizumab bests docetaxel in NSCLC
Tislelizumab was associated with better outcomes in patients with locally advanced or metastatic non–small cell lung cancer.
Conference Coverage
Antibiotics may prolong PFS in HCC patients on immunotherapy
Prior studies suggested that antibiotics reduce the efficacy of immunotherapy.